Molecular mechanisms and treatment targets of muscle wasting and cachexia in heart failure: An overview

Current Opinion in Supportive and Palliative Care

Volumn 8, Issue 1, 2014, Pages 15-24

  Ebner, Nicole ^a   Elsner, Sebastian ^a   Springer, Jochen ^a   Von Haehling, Stephan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cachexia; Heart failure; Muscle wasting; Sarcopenia

Indexed keywords

BIOLOGICAL MARKER; PROTEIN;

CACHEXIA; EXERCISE; EXERCISE TEST; HEART FAILURE; HUMAN; METABOLISM; MUSCLE ATROPHY; MUSCLE STRENGTH; PHYSIOLOGY; REVIEW; SARCOPENIA; SKELETAL MUSCLE;

BIOLOGICAL MARKERS; CACHEXIA; EXERCISE; EXERCISE TEST; HEART FAILURE; HUMANS; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR ATROPHY; PROTEINS; SARCOPENIA;

EID: 84897977038     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000030     Document Type: Review

References (69)

1. Zannad F, Garcia AA, Anker SD, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail 2013; 15:1082-1094. doi: 10.1093/ eurjhf/hft095.
2. von Haehling S, Jankowska EA, Ponikowski P, Anker SD. Anemia in heart failure: an overview of current concepts. Future Cardiol 2011; 7:119-129. doi: 10.2217/fca.10.110.
3. Fülster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J 2013; 34:512-519. doi: 10.1093/ eurheartj/ehs381.
4. Coats AJ. Research on cachexia, sarcopenia and skeletal muscle in cardiology. J Cachexia Sarcopenia Muscle 2012; 3:219-223. doi: 10.1007/ s13539-012-0090-6.
5. von Haehling S, Morley JE, Anker SD. From muscle wasting to sarcopenia and myopenia: update 2012. J Cachexia Sarcopenia Muscle 2012; 3:213-217. doi: 10.1007/s13539-012-0089-z.
6. Fearon K, Evans WJ, Anker SD. Myopenia-a new universal term for muscle wasting. J Cachexia Sarcopenia Muscle 2011; 2:1-3.
7. Morley JE, Abbatecola AM, Argiles JM, et al. Society on Sarcopenia, Cachexia and Wasting Disorders Trialist Workshop. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc 2011; 12:403-409. doi: 10.1016/j.jamda.2011.04.014.
8. Ebner N, Springer J, Kalantar-Zadeh K, et al. Mechanism and novel therapeutic approaches to wasting in chronic disease. Maturitas 2013; 75:199-206. doi: 10.1016/j.maturitas.2013.03.014.
9. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12:489-495. doi: 10.1016/S1470-2045(10)70218-7.
10. Evans WJ, Morley JE, Argilés J, et al. Cachexia: a new definition. Clin Nutr 2008; 27:793-799. doi: 10.1016/j.clnu.2008.06.013.
11. Rolland Y, Abellan Van Kana G, Gillette-Guyonnet S, Vellas B. Cachexia versus sarcopenia. Curr Opin Clin Nutr Metab Care 2011; 14: 15-21.
12. von Haehling S, Steinbeck L, Doehner W, et al. Muscle wasting in heart failure: an overview. Int J Biochem Cell Biol 2013; 45:2257-2265. doi: 10.1016/j.biocel.2013.04.025.
13. Utech AE, Tadros EM, Hayes TG, Garcia JM. Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. J Cachexia Sarcopenia Muscle 2012; 3:245-251. doi: 10.1007/ s13539-012-0075-5.
14. Kalantar-Zadeh K, Rhee C, Sim JJ, et al. Why cachexia kills: examining the causality of poor outcomes in wasting conditions. J Cachexia Sarcopenia Muscle 2013; 4:89-94. doi: 10.1007/s13539-013-0111-0.
15. Rozentryt P, von Haehling S, Lainscak M, et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachexia Sarcopenia Muscle 2010; 1:35-42.
16. Aquilani R, Opasich C, Gualco A, et al. Adequate energy-protein intake is not enough to improve nutritional and metabolic status in muscle-depleted patients with chronic heart failure. Eur J Heart Fail 2008; 10:1127-1135. doi: 10.1016/j.ejheart.2008.09.002.
17. Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind, placebocontrolled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998; 351:1233-1237.
18. Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004; 110:3674-3679.
19. Caminiti G, Volterrani M, Marazzi G, et al. Hydrotherapy added to endurance training versus endurance training alone in elderly patients with chronic heart failure: a randomized pilot study. Int J Cardiol 2011; 148:199-203. doi: 10.1016/j.ijcard.2009.09.565.
20. Iellamo F, Volterrani M, Caminiti G, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 2010; 56:1310-1316. doi: 10.1016/j.jacc. 2010.03.090.
21. Sandri M, Kozarez I, Adams V, et al. Age-related effects of exercise training on diastolic function in heart failure with reduced ejection fraction: the Leipzig Exercise Intervention in Chronic Heart Failure and Aging (LEICA) Diastolic Dysfunction Study. Eur Heart J 2012; 33:1758-1768. doi: 10. 1093/eurheartj/ehr469.
22. Gielen S, Sandri M, Kozarez I, et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study. Circulation 2012; 125:2716-2727. doi: 10.1161/CIRCULATIONAHA.111.047381.
23. Lenk K, Erbs S, Hö llriegel R, et al. Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure. Eur J Prev Cardiol 2012; 19:404-411. doi: 10.1177/1741826711402735.
24. Pu CT, Johnson MT, Forman DE, et al. Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. J Appl Physiol 2001; 90:2341-2350.
25. Hryniewicz K, Androne AS, Hudaihed A, Katz SD. Partial reversal of cachexia by beta-adrenergic receptor blocker therapy in patients with chronic heart failure. J Card Fail 2003; 9:464-468.
26. Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce antiinflammatory effects and improve body weight in severe heart failure. J Heart Lung Transplant 2006; 25:834-838.
27. Harrington D, Chua TP, Coats AJ. The effect of salbutamol on skeletal muscle in chronic heart failure. Int J Cardiol 2000; 73:257-265.
28. Dardevet D, Rémond D, Peyron MA, et al. Muscle wasting and resistance of muscle anabolism: the 'anabolic threshold concept' for adapted nutritional strategies during sarcopenia. Sci World J 2012; 2012:269531. doi: 10.1100/2012/269531.
29. Harrington D, Anker SD, Chua TP, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol 1997; 30:1758-1764.
30. Fanzani A, Conraads VM, Penna F, Martinet W. Molecular and cellular mechanisms of skeletal muscle atrophy: an update. J Cachexia Sarcopenia Muscle 2012; 3:163-179. doi: 10.1007/s13539-012-0074-6.
31. Nedergaard A, Karsdal MA, Sun S, Henriksen K. Serological muscle loss biomarkers: an overview of current concepts and future possibilities. J Cachexia Sarcopenia Muscle 2013; 4:1-17. doi: 10.1007/s13539-012-0086-2.
32. Scharf G, Heineke J. Finding good biomarkers for sarcopenia. J Cachexia Sarcopenia Muscle 2012; 3:145-148. doi: 10.1007/s13539-012-0081-7.
33. Cesari M, Fielding RA, Pahor M, et al. International Working Group on Sarcopenia. Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia. J Cachexia Sarcopenia Muscle 2012; 3:181-190. doi: 10.1007/s13539-012-0078-2.
34. Alamdari N, Aversa Z, Castillero E, Hasselgren PO. Acetylation and deacetylation: novel factors in muscle wasting. Metabolism 2013; 62:1-11. doi: 10.1016/j.metabol.2012.03.019.
35. Martins T, Vitorino R, Moreira-Gonçalves D, et al. Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia. Clin Biochem 2013; 31:8-14. doi:pii: S0009-9120(13)00499-2. 10.1016/ j.clinbiochem.2013.10.025.
36. Lee D, Goldberg AL. SIRT1 by blocking the activities of FoxO1 and 3 inhibits muscle atrophy and promotes muscle growth. J Biol Chem 2013; 288:30515-30526.
37. Baracos V, Kazemi-Bajestani SM. Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses. Int J Biochem Cell Biol 2013; 45:2302-2308. doi: 10.1016/j.biocel.2013.06.016.
38. Castillero E, Alamdari N, Lecker SH, Hasselgren PO. Suppression of atrogin-1 and MuRF1 prevents dexamethasone-induced atrophy of cultured myotubes. Metabolism 2013; 62:1495-1502. doi: 10.1016/j.metabol. 2013.05.018.
39. Marzetti E, Calvani R, Cesari M, et al. Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials. Int J Biochem Cell Biol 2013; 45:2288-2301. doi: 10.1016/j.biocel.2013.06.024.
40. Hö llriegel R, Beck EB, Linke A, et al. Anabolic effects of exercise training in patients with advanced chronic heart failure (NYHA IIIb): impact on ubiquitinprotein ligases expression and skeletal muscle size. Int J Cardiol 2013; 167:975-980. doi: 10.1016/j.ijcard.2012.03.083.
41. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14:803-869. doi: 10.1093/eurjhf/hfs105.
42. Shi J, Luo L, Eash J, et al. The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling. Dev Cell 2011; 21:835-847. doi: 10.1016/j.devcel.2011.09.011.
43. Sato S, Ogura Y, Mishra V, et al. TWEAK promotes exercise intolerance by decreasing skeletal muscle oxidative phosphorylation capacity. Skelet Muscle 2013; 3:18.
44. Sirabella D, De Angelis L, Berghella L. Sources for skeletal muscle repair: from satellite cells to reprogramming. J Cachexia Sarcopenia Muscle 2013; 4:125-136. doi: 10.1007/s13539-012-0098-y.
45. Scott IC, Tomlinson W, Walding A, et al. Large-scale isolation of human skeletal muscle satellite cells from postmortem tissue and development of quantitative assays to evaluate modulators of myogenesis. J Cachexia Sarcopenia Muscle 2013; 4:157-169. doi: 10.1007/s13539-012-0097-z.
46. Tran T, Andersen R, Sherman SP, Pyle AD. Insights into skeletal muscle development and applications in regenerative medicine. Int Rev Cell Mol Biol 2013; 300:51-83. doi: 10.1016/B978-0-12-405210-9.00002-3.
47. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126:663-676.
48. Strö mberg A, Jansson M, Fischer H, et al. Bone marrow derived cells in adult skeletal muscle tissue in humans. Skelet Muscle 2013; 3:12. doi: 10.1186/ 2044-5040-3-12.
49. Argiles JM, Busquets S, Orpi M, et al. Muscle wasting in cancer and ageing: cachexia versus sarcopenia. In: Lynch GS, editor. Sarcopenia-age-related muscle wasting and weakness. Springer Dordrecht Heidelberg; 2011. pp. 9-37.
50. Sakuma K, Yamaguchi A. Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. J Cachexia Sarcopenia Muscle 2012; 3:77-94. doi: 10.1007/s13539-011-0052-4.
51. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 2011; 12:249-256. doi: 10.1016/j.jamda.2011.01.003.
52. Marinangeli CP, Kassis AN. Use of dual X-ray absorptiometry to measure body mass during short- to medium-term trials of nutrition and exercise interventions. Nutr Rev 2013; 71:332-342.
53. Sillanpää E, Cheng S, Hä kkinen K, et al. Body composition in 18- to 88-yearold adults: comparison of multifrequency bioimpedance and dual-energy X-ray absorptiometry. Obesity (Silver Spring) 2013. doi: 10.1002/oby. 20583.
54. Zamboni M, Rossi AP, Corzato F, et al. Sarcopenia, cachexia and congestive heart failure in the elderly. Endocr Metab Immune Disord Drug Targets 2013; 13:58-67.
55. Villani AM, Miller MD, Cameron ID, et al. Development and relative validity of a new field instrument for detection of geriatric cachexia: preliminary analysis in hip fracture patients. J Cachexia Sarcopenia Muscle 2013; 4:209-216. doi: 10.1007/s13539-013-0108-8.
56. Hettwer S, Dahinden P, Kucsera S, et al. Elevated levels of a C-terminal agrin fragment identifies a new subset of sarcopenia patients. Exp Gerontol 2013; 48:69-75. doi: 10.1016/j.exger.2012.03.002.
57. Drey M, Sieber CC, Bauer JM, et al. FiAT intervention group. C-terminal agrin fragment as a potential marker for sarcopenia caused by degeneration of the neuromuscular junction. Exp Gerontol 2013; 48:76-80. doi: 10.1016/ j.exger.2012.05.021.
58. Bentzinger CF, Lin S, Romanino K, et al. Differential response of skeletal muscles to mTORC1 signaling during atrophy and hypertrophy. Skelet Muscle 2013; 3:6. doi: 10.1186/2044-5040-3-6.
59. Busquets S, Toledo M, Orpí M, et al. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle 2012; 3:37-43. doi: 10.1007/s13539-011-0049-z.
60. de Souza Vasconcelos KS, Dias JM, de Araújo MC, et al. Land-based versus aquatic resistance therapeutic exercises for older women with sarcopenic obesity: study protocol for a randomised controlled trial. Trials 2013; 14:296.
61. Elkina Y, von Haehling S, Anker SD, Springer J. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle 2011; 2:143-151.
62. Dioguardi FS. Clinical use of amino acids as dietary supplement: pros and cons. J Cachexia Sarcopenia Muscle 2011; 2:75-80.
63. Lenk K, Palus S, Schur R, et al. Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model. J Cachexia Sarcopenia Muscle 2013; 4:63-69. doi: 10.1007/s13539-012-0085- 3.
64. Webber CE, Barr RD. Age- and gender-dependent values of skeletal muscle mass in healthy children and adolescents. J Cachexia Sarcopenia Muscle 2012; 3:25-29. doi: 10.1007/s13539-011-0042-6.
65. Puppa MJ, White JP, Velázquez KT, et al. The effect of exercise on IL-6- induced cachexia in the Apc (Min/-) mouse. J Cachexia Sarcopenia Muscle 2012; 3:117-137. doi: 10.1007/s13539-011-0047-1.
66. Dideriksen K, Reitelseder S, Holm L. Influence of amino acids, dietary protein, and physical activity on muscle mass development in humans. Nutrients 2013; 5:852-876. doi: 10.3390/nu5030852.
67. Inui A. An invitation to the 7th Cachexia Conference, Kobe, Japan. J Cachexia Sarcopenia Muscle 2013; 4:171. doi: 10.1007/s13539-013-0118-6.
68. Ebner N, Werner CG, Doehner W, et al. Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference. J Cachexia Sarcopenia Muscle 2012; 3:45-50. doi: 10.1007/s13539-012-0061-y.
69. von Haehling S, Stepney R, Anker SD. Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference. Int J Cardiol 2010; 144:347-349. doi: 10.1016/j.ijcard.2010.05.042.